Algernon Pharmaceuticals engages ICP Securities for market making services

Algernon Pharmaceuticalshas engaged the services of ICP Securities to provide automated market making services, including use of its proprietary algorithm, ICP Premium. ICP will receive a fee of CDN $7,500 plus applicable taxes per month, payable monthly in advance. The agreement between the Company and ICP is for an Initial Term of three months and shall be automatically renewed for subsequent one month terms unless either party provides at least thirty days written notice prior to the end of the Initial Term or an Additional Term, as applicable. There are no performance factors contained in the agreement and no stock options or other compensation are being granted in connection with the engagement. ICP and its clients may acquire an interest in the securities of the Company in the future. ICP is an arm’s length party to the Company. ICP’s market making activity will be primarily to correct temporary imbalances in the supply and demand of the Company’s shares. ICP will be responsible for the costs it incurs in buying and selling the Company’s shares, and no third party will be providing funds or securities for the market making activities. The Company also announces a grant of 425,000 restricted share units pursuant to its RSU Plan to an employee and a consultant of the Company. Each RSU entitles the recipient to receive one common share of the Company or a cash payment equal to the equivalent of one common share of the Company on vesting. The RSUs vest on the date of grant. The RSUs are subject to approval by regulatory authorities.